aluates Reports

$ 0.0

Automative

Global IgA Nephropathy Drugs Market Research Report 2025

Published Date: March 2025

Report Code: QYRE-Auto-4V11702

Global IgA Nephropathy Drugs Market Research Report 2022

BUY CHAPTERS

Global IgA Nephropathy Drugs Market Research Report 2025

Code: QYRE-Auto-4V11702

Report

March 2025

Pages:74

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Travere Therapeutics

Omeros Corporation

Novartis International

Otsuka Pharmaceutical

Calliditas Therapeutics

Chinook Therapeutics

Vera Therapeutics

IgA Nephropathy Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

IgA Nephropathy Drugs Market

The global market for IgA Nephropathy Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

IgA nephropathy, also known as Berger"s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for IgA Nephropathy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding IgA Nephropathy Drugs.

The IgA Nephropathy Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global IgA Nephropathy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the IgA Nephropathy Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of IgA Nephropathy Drugs Market Report

Report Metric	Details
Report Name	IgA Nephropathy Drugs Market
CAGR	5%
Segment by Type	Phase I Phase II Phase III
Segment by Application	Clinical Treatment Drug Experiment
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Calliditas Therapeutics, Travere Therapeutics, Omeros Corporation, Novartis International, Chinook Therapeutics, Vera Therapeutics, Otsuka Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of IgA Nephropathy Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the IgA Nephropathy Drugs Market report?

Ans: The main players in the IgA Nephropathy Drugs Market are Calliditas Therapeutics, Travere Therapeutics, Omeros Corporation, Novartis International, Chinook Therapeutics, Vera Therapeutics, Otsuka Pharmaceutical

What are the Application segmentation covered in the IgA Nephropathy Drugs Market report?

Ans: The Applications covered in the IgA Nephropathy Drugs Market report are Clinical Treatment, Drug Experiment

What are the Type segmentation covered in the IgA Nephropathy Drugs Market report?

Ans: The Types covered in the IgA Nephropathy Drugs Market report are Phase I, Phase II, Phase III

Recommended Reports

Kidney Disease Drugs

Autoimmune & Immune Drugs

Digestive & Related Diseases

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global IgA Nephropathy Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Phase I

1.2.3 Phase II

1.2.4 Phase III

1.3 Market by Application

1.3.1 Global IgA Nephropathy Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Clinical Treatment

1.3.3 Drug Experiment

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global IgA Nephropathy Drugs Market Perspective (2020-2031)

2.2 Global IgA Nephropathy Drugs Growth Trends by Region

2.2.1 Global IgA Nephropathy Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 IgA Nephropathy Drugs Historic Market Size by Region (2020-2025)

2.2.3 IgA Nephropathy Drugs Forecasted Market Size by Region (2026-2031)

2.3 IgA Nephropathy Drugs Market Dynamics

2.3.1 IgA Nephropathy Drugs Industry Trends

2.3.2 IgA Nephropathy Drugs Market Drivers

2.3.3 IgA Nephropathy Drugs Market Challenges

2.3.4 IgA Nephropathy Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top IgA Nephropathy Drugs Players by Revenue

3.1.1 Global Top IgA Nephropathy Drugs Players by Revenue (2020-2025)

3.1.2 Global IgA Nephropathy Drugs Revenue Market Share by Players (2020-2025)

3.2 Global IgA Nephropathy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by IgA Nephropathy Drugs Revenue

3.4 Global IgA Nephropathy Drugs Market Concentration Ratio

3.4.1 Global IgA Nephropathy Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by IgA Nephropathy Drugs Revenue in 2024

3.5 Global Key Players of IgA Nephropathy Drugs Head office and Area Served

3.6 Global Key Players of IgA Nephropathy Drugs, Product and Application

3.7 Global Key Players of IgA Nephropathy Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 IgA Nephropathy Drugs Breakdown Data by Type

4.1 Global IgA Nephropathy Drugs Historic Market Size by Type (2020-2025)

4.2 Global IgA Nephropathy Drugs Forecasted Market Size by Type (2026-2031)

5 IgA Nephropathy Drugs Breakdown Data by Application

5.1 Global IgA Nephropathy Drugs Historic Market Size by Application (2020-2025)

5.2 Global IgA Nephropathy Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America IgA Nephropathy Drugs Market Size (2020-2031)

6.2 North America IgA Nephropathy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America IgA Nephropathy Drugs Market Size by Country (2020-2025)

6.4 North America IgA Nephropathy Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe IgA Nephropathy Drugs Market Size (2020-2031)

7.2 Europe IgA Nephropathy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe IgA Nephropathy Drugs Market Size by Country (2020-2025)

7.4 Europe IgA Nephropathy Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific IgA Nephropathy Drugs Market Size (2020-2031)

8.2 Asia-Pacific IgA Nephropathy Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific IgA Nephropathy Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific IgA Nephropathy Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America IgA Nephropathy Drugs Market Size (2020-2031)

9.2 Latin America IgA Nephropathy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America IgA Nephropathy Drugs Market Size by Country (2020-2025)

9.4 Latin America IgA Nephropathy Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa IgA Nephropathy Drugs Market Size (2020-2031)

10.2 Middle East & Africa IgA Nephropathy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa IgA Nephropathy Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa IgA Nephropathy Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Calliditas Therapeutics

11.1.1 Calliditas Therapeutics Company Details

11.1.2 Calliditas Therapeutics Business Overview

11.1.3 Calliditas Therapeutics IgA Nephropathy Drugs Introduction

11.1.4 Calliditas Therapeutics Revenue in IgA Nephropathy Drugs Business (2020-2025)

11.1.5 Calliditas Therapeutics Recent Development

11.2 Travere Therapeutics

11.2.1 Travere Therapeutics Company Details

11.2.2 Travere Therapeutics Business Overview

11.2.3 Travere Therapeutics IgA Nephropathy Drugs Introduction

11.2.4 Travere Therapeutics Revenue in IgA Nephropathy Drugs Business (2020-2025)

11.2.5 Travere Therapeutics Recent Development

11.3 Omeros Corporation

11.3.1 Omeros Corporation Company Details

11.3.2 Omeros Corporation Business Overview

11.3.3 Omeros Corporation IgA Nephropathy Drugs Introduction

11.3.4 Omeros Corporation Revenue in IgA Nephropathy Drugs Business (2020-2025)

11.3.5 Omeros Corporation Recent Development

11.4 Novartis International

11.4.1 Novartis International Company Details

11.4.2 Novartis International Business Overview

11.4.3 Novartis International IgA Nephropathy Drugs Introduction

11.4.4 Novartis International Revenue in IgA Nephropathy Drugs Business (2020-2025)

11.4.5 Novartis International Recent Development

11.5 Chinook Therapeutics

11.5.1 Chinook Therapeutics Company Details

11.5.2 Chinook Therapeutics Business Overview

11.5.3 Chinook Therapeutics IgA Nephropathy Drugs Introduction

11.5.4 Chinook Therapeutics Revenue in IgA Nephropathy Drugs Business (2020-2025)

11.5.5 Chinook Therapeutics Recent Development

11.6 Vera Therapeutics

11.6.1 Vera Therapeutics Company Details

11.6.2 Vera Therapeutics Business Overview

11.6.3 Vera Therapeutics IgA Nephropathy Drugs Introduction

11.6.4 Vera Therapeutics Revenue in IgA Nephropathy Drugs Business (2020-2025)

11.6.5 Vera Therapeutics Recent Development

11.7 Otsuka Pharmaceutical

11.7.1 Otsuka Pharmaceutical Company Details

11.7.2 Otsuka Pharmaceutical Business Overview

11.7.3 Otsuka Pharmaceutical IgA Nephropathy Drugs Introduction

11.7.4 Otsuka Pharmaceutical Revenue in IgA Nephropathy Drugs Business (2020-2025)

11.7.5 Otsuka Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Travere Therapeutics

Omeros Corporation

Novartis International

Otsuka Pharmaceutical

Calliditas Therapeutics

Chinook Therapeutics

Vera Therapeutics

List of Tables

Table 1. Global IgA Nephropathy Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Phase I

Table 3. Key Players of Phase II

Table 4. Key Players of Phase III

Table 5. Global IgA Nephropathy Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global IgA Nephropathy Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global IgA Nephropathy Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global IgA Nephropathy Drugs Market Share by Region (2020-2025)

Table 9. Global IgA Nephropathy Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global IgA Nephropathy Drugs Market Share by Region (2026-2031)

Table 11. IgA Nephropathy Drugs Market Trends

Table 12. IgA Nephropathy Drugs Market Drivers

Table 13. IgA Nephropathy Drugs Market Challenges

Table 14. IgA Nephropathy Drugs Market Restraints

Table 15. Global IgA Nephropathy Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global IgA Nephropathy Drugs Market Share by Players (2020-2025)

Table 17. Global Top IgA Nephropathy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IgA Nephropathy Drugs as of 2024)

Table 18. Ranking of Global Top IgA Nephropathy Drugs Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by IgA Nephropathy Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of IgA Nephropathy Drugs, Headquarters and Area Served

Table 21. Global Key Players of IgA Nephropathy Drugs, Product and Application

Table 22. Global Key Players of IgA Nephropathy Drugs, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global IgA Nephropathy Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global IgA Nephropathy Drugs Revenue Market Share by Type (2020-2025)

Table 26. Global IgA Nephropathy Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global IgA Nephropathy Drugs Revenue Market Share by Type (2026-2031)

Table 28. Global IgA Nephropathy Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global IgA Nephropathy Drugs Revenue Market Share by Application (2020-2025)

Table 30. Global IgA Nephropathy Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global IgA Nephropathy Drugs Revenue Market Share by Application (2026-2031)

Table 32. North America IgA Nephropathy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America IgA Nephropathy Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America IgA Nephropathy Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe IgA Nephropathy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe IgA Nephropathy Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe IgA Nephropathy Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific IgA Nephropathy Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific IgA Nephropathy Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific IgA Nephropathy Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America IgA Nephropathy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America IgA Nephropathy Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America IgA Nephropathy Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa IgA Nephropathy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa IgA Nephropathy Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa IgA Nephropathy Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 47. Calliditas Therapeutics Company Details

Table 48. Calliditas Therapeutics Business Overview

Table 49. Calliditas Therapeutics IgA Nephropathy Drugs Product

Table 50. Calliditas Therapeutics Revenue in IgA Nephropathy Drugs Business (2020-2025) & (US$ Million)

Table 51. Calliditas Therapeutics Recent Development

Table 52. Travere Therapeutics Company Details

Table 53. Travere Therapeutics Business Overview

Table 54. Travere Therapeutics IgA Nephropathy Drugs Product

Table 55. Travere Therapeutics Revenue in IgA Nephropathy Drugs Business (2020-2025) & (US$ Million)

Table 56. Travere Therapeutics Recent Development

Table 57. Omeros Corporation Company Details

Table 58. Omeros Corporation Business Overview

Table 59. Omeros Corporation IgA Nephropathy Drugs Product

Table 60. Omeros Corporation Revenue in IgA Nephropathy Drugs Business (2020-2025) & (US$ Million)

Table 61. Omeros Corporation Recent Development

Table 62. Novartis International Company Details

Table 63. Novartis International Business Overview

Table 64. Novartis International IgA Nephropathy Drugs Product

Table 65. Novartis International Revenue in IgA Nephropathy Drugs Business (2020-2025) & (US$ Million)

Table 66. Novartis International Recent Development

Table 67. Chinook Therapeutics Company Details

Table 68. Chinook Therapeutics Business Overview

Table 69. Chinook Therapeutics IgA Nephropathy Drugs Product

Table 70. Chinook Therapeutics Revenue in IgA Nephropathy Drugs Business (2020-2025) & (US$ Million)

Table 71. Chinook Therapeutics Recent Development

Table 72. Vera Therapeutics Company Details

Table 73. Vera Therapeutics Business Overview

Table 74. Vera Therapeutics IgA Nephropathy Drugs Product

Table 75. Vera Therapeutics Revenue in IgA Nephropathy Drugs Business (2020-2025) & (US$ Million)

Table 76. Vera Therapeutics Recent Development

Table 77. Otsuka Pharmaceutical Company Details

Table 78. Otsuka Pharmaceutical Business Overview

Table 79. Otsuka Pharmaceutical IgA Nephropathy Drugs Product

Table 80. Otsuka Pharmaceutical Revenue in IgA Nephropathy Drugs Business (2020-2025) & (US$ Million)

Table 81. Otsuka Pharmaceutical Recent Development

Table 82. Research Programs/Design for This Report

Table 83. Key Data Information from Secondary Sources

Table 84. Key Data Information from Primary Sources

Table 85. Authors List of This Report

List of Figures

Figure 1. IgA Nephropathy Drugs Picture

Figure 2. Global IgA Nephropathy Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global IgA Nephropathy Drugs Market Share by Type: 2024 VS 2031

Figure 4. Phase I Features

Figure 5. Phase II Features

Figure 6. Phase III Features

Figure 7. Global IgA Nephropathy Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global IgA Nephropathy Drugs Market Share by Application: 2024 VS 2031

Figure 9. Clinical Treatment Case Studies

Figure 10. Drug Experiment Case Studies

Figure 11. IgA Nephropathy Drugs Report Years Considered

Figure 12. Global IgA Nephropathy Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global IgA Nephropathy Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global IgA Nephropathy Drugs Market Share by Region: 2024 VS 2031

Figure 15. Global IgA Nephropathy Drugs Market Share by Players in 2024

Figure 16. Global Top IgA Nephropathy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IgA Nephropathy Drugs as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by IgA Nephropathy Drugs Revenue in 2024

Figure 18. North America IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America IgA Nephropathy Drugs Market Share by Country (2020-2031)

Figure 20. United States IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe IgA Nephropathy Drugs Market Share by Country (2020-2031)

Figure 24. Germany IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific IgA Nephropathy Drugs Market Share by Region (2020-2031)

Figure 32. China IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America IgA Nephropathy Drugs Market Share by Country (2020-2031)

Figure 40. Mexico IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa IgA Nephropathy Drugs Market Share by Country (2020-2031)

Figure 44. Turkey IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE IgA Nephropathy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Calliditas Therapeutics Revenue Growth Rate in IgA Nephropathy Drugs Business (2020-2025)

Figure 48. Travere Therapeutics Revenue Growth Rate in IgA Nephropathy Drugs Business (2020-2025)

Figure 49. Omeros Corporation Revenue Growth Rate in IgA Nephropathy Drugs Business (2020-2025)

Figure 50. Novartis International Revenue Growth Rate in IgA Nephropathy Drugs Business (2020-2025)

Figure 51. Chinook Therapeutics Revenue Growth Rate in IgA Nephropathy Drugs Business (2020-2025)

Figure 52. Vera Therapeutics Revenue Growth Rate in IgA Nephropathy Drugs Business (2020-2025)

Figure 53. Otsuka Pharmaceutical Revenue Growth Rate in IgA Nephropathy Drugs Business (2020-2025)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

Figure 56. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Renal Therapeutic Market Research Report 2025

Global Complement Drug for Kidney Disease Market Research Report 2024

Chronic Kidney Disease CKD Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

End Stage Renal Disease Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Late Stage Chronic Kidney Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global IgA Nephropathy Treatment Market Research Report 2025

Kidney Renal Fibrosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Membranous Nephropathy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Kidney Medicine Market Insights Forecast to 2030

Global Focal Glomerular Sclerosis FSGS Treatment Medicine Market Research Report 2025

C3 Glomerulopathy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Drugs to Treat Chronic Kidney Disease Market Research Report 2024

Kidney Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Focal Nodular Glomerulosclerosis FSGS Treatment Medicine Market Research Report 2025

Global Chronic Kidney Disease CKD Treatment Market Research Report 2025

Global Chronic Kidney Disease Medication Market Research Report 2024

Global End Stage Renal Disease ESRD Treatment Market Research Report 2025

Lupus Nephritis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Idiopathic Membranous Nephropathy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions